Legislation related to spinal cord injury research and treatment.
2026 · 2nd Quarter (Apr 1 - June 30)
NERVGEN PHARMA CORP.
Filed by CORNERSTONE GOVERNMENT AFFAIRS, INC..
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 10, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- CORNERSTONE GOVERNMENT AFFAIRS, INC.
- Client
- NERVGEN PHARMA CORP.
- Filing UUID
- 4d2f42ff-8ae9-45c8-a0ce-e2e97a205482
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Legislation related to central nervous system research and therapeutics.
Legislation related to spinal cord injury research, therapeutics and approvals.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.